Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients
- PMID: 1096218
- DOI: 10.1007/BF00421473
Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients
Abstract
8 male schizophrenic patients participated in a double-blind, cross over study of the extrapyramidal side-effects of haloperidol and clozapine (acute dystonis, Parkinsonism and tardive dyskinesia), together with their effect on homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) in the cerebrospinal fluid (CSF). Haloperidol (9 mg/day) caused Parkinsonism, reduced tardive dyskinesias and increased the HVA concentration in the CSF. Clozapine (225 mg/day) had no effect on the neurological phenomena but reduced HVA and 5-HIAA concentrations in the CSF. During the discontinuation phase following the administration of haloperidol, tardive dyskinesia occurred or was aggravated; this did not occur after administration of clozapine. Accordingly, it is suggested that clozapine does not induce dopaminergic hypersensibility and, therefore, will not induce tardive dyskinesias.
Similar articles
-
Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol.Pharmakopsychiatr Neuropsychopharmakol. 1976 Jan;9(1):33-6. doi: 10.1055/s-0028-1094475. Pharmakopsychiatr Neuropsychopharmakol. 1976. PMID: 981320
-
Clinical and biochemical parameters during neuroleptic treatment. II. Antipsychotic effect of haloperidol in patients with chronic organic brain damage.Pharmakopsychiatr Neuropsychopharmakol. 1976 Jan;9(1):37-42. doi: 10.1055/s-0028-1094476. Pharmakopsychiatr Neuropsychopharmakol. 1976. PMID: 981321
-
Clozapine pharmacology and tardive dyskinesia.Psychopharmacology (Berl). 1989;99 Suppl:S54-9. doi: 10.1007/BF00442560. Psychopharmacology (Berl). 1989. PMID: 2479047
-
Clozapine: neuroleptic-induced EPS and tardive dyskinesia.Psychopharmacology (Berl). 1989;99 Suppl:S47-53. doi: 10.1007/BF00442559. Psychopharmacology (Berl). 1989. PMID: 2682732 Review.
-
Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia.J Clin Psychiatry. 1998;59 Suppl 3:31-7. J Clin Psychiatry. 1998. PMID: 9541336 Review.
Cited by
-
Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia.Neuropharmacology. 2018 Jul 1;136(Pt C):438-448. doi: 10.1016/j.neuropharm.2017.09.012. Epub 2017 Sep 9. Neuropharmacology. 2018. PMID: 28893562 Free PMC article. Review.
-
Early relapse after sudden withdrawal or dose reduction of clozapine.Psychopharmacology (Berl). 1985;86(1-2):244. doi: 10.1007/BF00431719. Psychopharmacology (Berl). 1985. PMID: 3927364 No abstract available.
-
Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia--a retrospective study of 387 patients.Psychopharmacology (Berl). 1989;99 Suppl:S73-6. doi: 10.1007/BF00442564. Psychopharmacology (Berl). 1989. PMID: 2813668
-
Cholinergic mediation of the discriminative stimulus properties of clozapine.Psychopharmacology (Berl). 1988;94(1):115-8. doi: 10.1007/BF00735891. Psychopharmacology (Berl). 1988. PMID: 3126519
-
Tardive dyskinesia: a clinical test of the supersensitivity hypothesis.Psychopharmacology (Berl). 1979 Mar 22;61(2):137-41. doi: 10.1007/BF00426727. Psychopharmacology (Berl). 1979. PMID: 220654 Clinical Trial.